Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04793568
Other study ID # RC20_0082
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date March 29, 2021
Est. completion date June 2023

Study information

Verified date February 2022
Source Nantes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PREV-HAP study is part of a larger project entitled 'Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia' (HAP2), funded by the European Union's H2020 research and innovation programme under grant agreement N°847782. HAP2 aims to develop stratified host-directed drugs and biomarkers to enhance the prevention and the treatment of HAP and develop precision medicine in infectious diseases. Its ambition is to revolutionize the management of HAP: capitalising on the novel concept of critical-illness related immunosuppression altering the host-pathogens interactions, the aim is to propose a complete reappraisal of the physiopathology of HAP based on the concept of respiratory dysbiosis. The main hypothesis of the PREV-HAP study is that human recombinant Interferon gamma 1b (rHuIFN-γ, Imukin) treatment can restore immunity in critically ill patients and prevent Hospital-Acquired Pneumonia. The hypothesesis is that the in vivo investigations of the host-pathogens interactions can be used for the stratification of patients into high/low risk and responders/non-responders to host-targeted prevention of hospital-acquired infections. The involvement of a state of critical-illness related immunosuppression in the susceptibility to hospital-acquired pneumonia is widely accepted, and an emerging trend is that the development of drugs for the treatment of this acquired immunosuppression will prevent infection and enhance outcomes of hospitalized patients. It has been demonstrated that the productions of IFN-γ by immune cells are decreased in critically ill patients, and that these defects are associated with the susceptibility to HAP. rHuIFN-γ has neither been tested nor is recommended as adjunctive treatment of patients with HAP. Based on these specific factors identified in the host response, it is proposed in this study to use rHuIFN-γ as novel preventive approach for HAP.


Description:

200 adult patients hospitalized in intensive care units, under mechanical ventilation in three European countries will be included in the trial, and will be randomized in 2 arms : Arm 1 (rHu-IFNγ): • Recombinant Interferon gamma 1b (IMUKIN®, from Clinigen®): 100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h), Arm 2 (Placebo): • Recombinant Interferon gamma 1b placebo: 5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).


Read more »

Study Design


Intervention

Drug:
Recombinant Interferon gamma 1b (IMUKIN®)
100 µg/0,5ml subcutaneous injections from day 1 to day 9 (5 injections, i.e. 1 injection of 100 µg every 48h)
Recombinant Interferon gamma 1b placebo
5 subcutaneous injections from day 1 to day 9 (i.e. 1 injection of 0,5ml every 48h).

See more »

Sponsors (1)

Lead Sponsor Collaborator
Nantes University Hospital

Countries where clinical trial is conducted

France,  Greece,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary To demonstrate the efficiency of rHuIFN-? for the prevention of hospital-acquired pneumonia Rate of the composite outcome at day 28 made of at least one item among the following: all cause mortality and/or hospital-acquired pneumonia Day 28
Secondary All-cause mortality [efficiency of rHu-IFN-?, on pneumonia-associated morbidity and mortality reduction] Rate of all-cause mortality at D28 and D90 Day 28 and Day 90
Secondary Rate of HAP [efficiency] Rate of HAP at D28 Day 28
Secondary Bacterial ecology of the 1st episode of HAP [efficiency] Bacterial ecology of the 1st episode of HAP (respiratory fluids) Day 28
Secondary Rate of ventilator-associated tracheobronchitis [efficiency] Rate of ventilator-associated tracheobronchitis at D28 defined as at least two of the following criteria: body temperature >38°C; leukocytosis>12000 cells/mL, leucopenia <4000 cells/mL, or purulent pulmonary secretions and a positive culture of a respiratory tract samples, without appearance of a new infiltrate or change in an existing infiltrate on chest radiography Day 28
Secondary Occurence of Acute Respiratory Distress Syndrome [efficiency] Acute Respiratory Distress Syndrome within 28 days after randomization Day 28
Secondary Duration of antimicrobial therapy [efficiency] Duration of antimicrobial therapy at D28, antibiotic free days at D28 Day 28
Secondary Duration of mechanical ventilation [efficiency] Duration of mechanical ventilation at D90, mechanical ventilation free days at D90 Day 90
Secondary Duration of ICU hospitalization [efficiency] Duration of ICU hospitalization at D90, Duration of hospitalization at D90. Day 90
Secondary Rate of SAEs and SUSARs [tolerance] Rate of serious adverse effects and suspected unexpected serious adverse reaction (SUSAR) at D15 Day 15
Secondary Rate of leukocytosis [tolerance] Rate of leukocytosis at D15. Day 15
Secondary Rate of neutropenia [tolerance] Rate of neutropenia at D15. Day 15
Secondary Rate of lymphopenia [tolerance] Rate of lymphopenia at D15. Day 15
Secondary Rate of thrombopenia [tolerance] Rate of thrombopenia at D15. Day 15
Secondary Rate of liver cytolysis [tolerance] Rate of liver cytolysis (Increases in AST and/or ALT) at D15. Day 15
Secondary Rate of pancreatitis [tolerance] Rate of pancreatitis (Increase in Lipase) at D15. Day 15
Secondary Rate of patients with episode of fever [tolerance] Rate of patients with episode of fever (T° > 38.3°C) Day 15
Secondary Rate of patients with episode of headache [tolerance] Rate of patients with episode of headache Day 15
Secondary Rate of patients with episode of nausea [tolerance] Rate of patients with episode of nausea Day 15
Secondary Rate of allergic reaction [tolerance] Rate of major allergic reaction at D15 defined as systemic epidermic reaction, anaphylactic Day 15
Secondary Incidence of injection site reaction [tolerance] Occurence of injection site reaction at D15 Day 15
Secondary Rate of myalgia [tolerance] Rate of myalgia at D15 Day 15
Secondary Rate of arthralgia [tolerance] Rate of arthralgia at D15 Day 15
Secondary Rate of back pain [tolerance] Rate of back pain at D15 Day 15
Secondary Economic efficiency of rHu-IFN-? in the prevention of pneumonia Economic endpoint at 3 months: Incremental cost effectiveness ratio (ICER). Analysis using QALYs (Quality-Adjusted Life-Years) as a measure of effectiveness. QALYs are a measure of effectiveness specifically designed for economic evaluations. Day 90
Secondary To determine the suitability of rHu-IFN-? from the patients' and relatives' perspectives using The Short Form (36) Health Survey Changes in health-related quality of life (HRQoL) from one (M1) to three months (M3) after randomization measured with the Short Form (SF)-36 scale validated in French, Greek, and Spanish he SF-36 is a 36-item self-report questionnaire with 8 domains = Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health).The scores of each domain range from 0 to 100, a higher score indicating a better HRQoL. Day 90
Secondary To determine the suitability of rHu-IFN-? from the patients' and relatives' perspectives using the Hospital Anxiety and Depression scale (HADS) Changes in anxiety and depression from M1 to M3 measured with the HADS scale validated in French, Greek, and Spanish. The HADS is a 14-item self-report questionnaire with 2 domains (anxietyand depression).
The scores for anxiety and depression range from 0 (no symptoms) to 21 (significant number of symptoms).
Day 90
Secondary To determine the suitability of rHu-IFN-? from the patients' and relatives' perspectives using Satisfaction With Life Scale (SWLS) Changes in subjective well-being from M1 to M3 measured with the Satisfaction With Life Scale (SWLS) validated in French, Greek, and Spanish. The SWLS is a 5-item self-report questionnaire. The response scores to the five items are added together to provide a total score ranging from 5 (worst satisfaction level) to 35 (best level). Day 90
Secondary To determine the acceptability of rHu-IFN-? from the patients' and relatives' perspectives Adaptation of the patients to their health state and its evolution from M1 to M3 using differential item functioning and response shift analyses for HRQoL, anxiety and depression. Change in the meaning of patients' self-evaluation between groups (DIF) and over time (response shift) will be inferred by the change in the items' parameters of the Partial Credit Models. Day 90
See also
  Status Clinical Trial Phase
Recruiting NCT04045366 - Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients
Completed NCT01411553 - ECG Leadwires: Disposable Versus Cleaned, Reusable N/A
Completed NCT00288743 - Adherence, Efficacy and Safety of an Insulin Protocol in the Critically Ill: A Prospective Observational Study Phase 2
Recruiting NCT03529617 - Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates
Not yet recruiting NCT05564975 - Construction and Application of Pressure Injury Risk Prediction Model for Critically Ill Patients
Recruiting NCT06234787 - Continuous Subcutaneous Glucose Monitoring in Critical Patients
Completed NCT02198950 - Combined Determination of sTREM-1, PCT and CD64 in Diagnosing Sepsis
Recruiting NCT01317381 - ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill Phase 4
Completed NCT00470821 - Oral Melatonin in Critically Ill High-risk Patients Phase 4
Completed NCT00460252 - Tight Glycemic Control by eMPC Algorithm in Medical ICU Patients. N/A
Recruiting NCT06049979 - Correlation Between Intestinal Blood Flow and Intestinal Dysfunction in Critically Ill Patients
Recruiting NCT05458687 - Traditional Chinese Medicine for Complications in Critically Ill Patients N/A
Completed NCT01963013 - Non-returning Catheter Valve for Reducing CAUTI N/A
Completed NCT01794468 - A New Monitor to Measure Dermal Blood Flow in Critically Ill Patients: a Preliminary Study N/A
Completed NCT03469882 - High Protein Intake and Early Exercise in Adult Intensive Care Patients N/A
Recruiting NCT04962204 - Virtual Visitation in Intensive Care Unit Study N/A
Completed NCT03205592 - Ultrasound Assessment of Residual Gastric Content in Critically Ill Patients
Recruiting NCT01995565 - Regional Cerebral Hemodynamics Related to Global Hemodynamics N/A
Completed NCT00143494 - The Estimation of Abdominal Pressure by the Bladder and Gastric Pressure N/A
Completed NCT00590928 - Gastric pH in Critically Ill Patients Phase 4